INSTITUT CURIE

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Established: 1909-01-01

Employees: 1K

Market Cap: -

Website: http://www.curie.fr

Clinical Trials

Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds

Phase 3

Terminated

Conditions: Local Pain
Chronic Wounds

Interventions: Drug: Morphine gel
Other: Neutral gel

First Posted Date: 2014-01-07

Last Posted Date: 2016-11-21

Lead Sponsor: Institut Curie

Target Recruit Count: 126

Registration Number: NCT02028923

Locations: 🇫🇷
Hôpital Louis Mourier, Colombes, Ile de France, France
🇫🇷
Hôpital Jean-Jaurès, Paris, Ile de France, France
🇫🇷
Institut Curie - Hôpital René Huguenin, Saint-Cloud, Ile de France, France

and more 2 locations

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

Phase 2

Completed

Conditions: Metastatic Breast Cancer, HER2 Negative Primary Tumor

Interventions: Drug: Trastuzumab - Emtansine

First Posted Date: 2013-11-03

Last Posted Date: 2019-03-21

Lead Sponsor: Institut Curie

Target Recruit Count: 155

Registration Number: NCT01975142

Locations: 🇫🇷
Chu de Limoges, Limoges, France
🇫🇷
Chu Saint-Louis, Paris, France
🇫🇷
Clinique Victor Hugo, Le Mans, France

and more 7 locations

Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE)

Not Applicable

Terminated

Conditions: Metastatic Breast Cancer

First Posted Date: 2013-10-08

Last Posted Date: 2024-01-31

Lead Sponsor: Institut Curie

Target Recruit Count: 130

Registration Number: NCT01956552

Locations: 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷
Institut Curie, Paris, France

and more 3 locations

Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma

Phase 2

Completed

Conditions: Relapse
Lymphoma

Interventions: Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2013-10-08

Last Posted Date: 2020-12-17

Lead Sponsor: Institut Curie

Target Recruit Count: 45

Registration Number: NCT01956695

Locations: 🇫🇷
CHU Bretonneau - Centre Henry Kaplan, Tours, Centre, France
🇫🇷
Chu La Timone, Marseille, France
🇫🇷
Hôpital de la Pitié Salpétrière, Paris, Ile De France, France

and more 9 locations

Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

Phase 3

Active, not recruiting

Conditions: Neuroblastoma
Opsoclonus Myoclonus Syndrome

Interventions: Drug: Dexamethasone acetate
Drug: dexamethasone and cyclophosphamide
Drug: dexamethasone and rituximab

First Posted Date: 2013-06-04

Last Posted Date: 2024-01-31

Lead Sponsor: Institut Curie

Target Recruit Count: 102

Registration Number: NCT01868269

Locations: 🇫🇷
Chu Amiens, Amiens, France
🇦🇹
St. Anna Kinderkrebsforschung e.V. CHILDREN'S CANCER RESEARCH INSTITUTE, Wien, Austria
🇫🇷
Chu de Bicetre, Le Kremlin-Bicêtre, LE Kremlin Bicetre, France

and more 33 locations

A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

Phase 2

Conditions: Reccurent/Metastatic Solid Tumor Disease

Interventions: Procedure: Tumor biopsy
Drug: Standard Chemotherapy

First Posted Date: 2013-01-18

Last Posted Date: 2016-07-13

Lead Sponsor: Institut Curie

Target Recruit Count: 742

Registration Number: NCT01771458

Locations: 🇫🇷
Insitut Curie, Paris, France
🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷
Centre régional de lutte contre le cancer de Bourgogne Georges François Leclerc, Dijon, France

and more 5 locations

Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers

Phase 3

Conditions: Hormone-receptors Positive Breast Cancer
Ductal Infiltrating Metastatic Breast Cancer

Interventions: Biological: Circulating tumor cells counting at baseline

First Posted Date: 2012-10-19

Last Posted Date: 2018-04-09

Lead Sponsor: Institut Curie

Target Recruit Count: 800

Registration Number: NCT01710605

Locations: 🇫🇷
Centre Georges Francois Leclerc, Dijon, France
🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷
Institut Paoli Calmettes, Marseille, France

and more 14 locations

COsegregation of VARiants in Panel of Genes

Not Applicable

Recruiting

Conditions: Genetic Predisposition
Gene Mutation-Related Cancer

Interventions: Genetic: salivary kit

First Posted Date: 2012-09-21

Last Posted Date: 2024-01-17

Lead Sponsor: Institut Curie

Target Recruit Count: 3500

Registration Number: NCT01689584

Locations: 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
CHU Bretonneau, Tours, France
🇲🇶
CHU de Fort de France, Fort de France, Martinique

and more 54 locations

Post-occlusive Reactive Hyperemia and Basal-cell Carcinoma

Not Applicable

Completed

Conditions: Carcinoma, Basal Cell

First Posted Date: 2011-10-19

Last Posted Date: 2012-04-04

Lead Sponsor: Institut Curie

Target Recruit Count: 12

Registration Number: NCT01455363

Locations: 🇫🇷
Institut Curie, Paris, France

Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel

Not Applicable

Completed

Conditions: Tumors

First Posted Date: 2011-10-07

Last Posted Date: 2015-04-24

Lead Sponsor: Institut Curie

Target Recruit Count: 30

Registration Number: NCT01448759

Locations: 🇫🇷
Institut Curie, Paris, France

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy